ALS Biomarker Collaboration – Call for Biomarker Discovery ProjectsIn The Media
The ALS Association and ALS Finding a Cure (ALS FAC) are pleased to announce a call for biomarker discovery projects. The call for proposals is open to academia and industry world-wide and is part of a broader initiative, the "ALS Biomarker Collaboration," encouraging the development of new biomarkers in a pre-competitive space. Proposed projects should be completed over 12-18 months.
ALS ACT (Accelerated Therapeutics)
Request for Proposals: Early phase clinical development of novel, high-potential treatments for people with ALSIn The Media
ALS Finding a Cure (ALS FAC), the ALS Association (ALSA) and the Northeast ALS Consortium (NEALS) are pleased to announce a call for phase I/II clinical trial applications for novel, high-potential treatments in Amyotrophic Lateral Sclerosis – ALS ACT. The call for clinical study proposals is intended for academic-industry partnerships, including pharmaceutical, biotherapeutic/biotechnology companies, academic members of NEALS, and ALS scientists throughout the world. Read the full press release below.
Clinical Trial: ALS Association and ALS Finding a Cure® Supported Phase II RNS60 Trial is Now EnrollingIn The Media
The clinical trial to test RNS60, a new compound for the treatment of ALS, which was supported in part from a $1.0 million grant through the ALS ACT initiative funded by The ALS Association and ALS Finding A Cure®, is now actively enrolling. This randomized placebo-controlled phase II study is being run by the IRCCS Mario Negri Institute for Pharmacological Research in Milan and the ALS Center of the Maggiore University Hospital in Novara Italy. We are happy to report that the first patient was dosed in mid-July 2017.